Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

CVS: By the Numbers: Real-World Impact of Rising Drug Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/16/2017 | 01:55pm CEST

Release date- 15062017 - CVS Health - Prescription drug prices continue to be a serious concern as rising prices outpace overall health care inflation. In 2015 alone, 16.7 percent of all U.S. health care dollars was spent on prescription drugs.

This rise in costs not only places a heavy burden on patients and payors, it ultimately affects U.S. taxpayers. To understand the real-world impact of rising drug costs on Americans, we conducted a survey of 2,195 registered voters in April 2017.

Voters are Overwhelmingly Concerned

Eighty-eight percent of respondents report being somewhat or very concerned about the high cost of prescription drugs. A higher percentage of women than men report being very concerned about drug prices (60 percent vs. 47 percent, respectively). Voters aged 45-65 are more likely to report concern than their younger counterparts, as are voters who take three or more prescription drugs.

Many Believe Increasing Competition and Accelerating Drug Reviews Can Help

Nearly one in two (47 percent) voters believe that there aren't enough different prescription drugs available to patients to treat their diseases and conditions. Forty-seven percent also believe that there is not enough competition in the pharmaceutical marketplace. Among voters aged 55-64, that number jumps to 60 percent.

There is, however, majority support for quicker market entry of lower-cost alternatives to brand-name drugs. Fifty-eight percent of respondents are supportive of proposals to speed up FDA approval of biosimilar drugs, which are near-identical copies of original biologic products; this means that there are no clinically significant differences in safety and efficacy.

CVS Health is Committed to Making Medications More Accessible and Affordable

We employ industry-leading strategies to encourage more competitive pricing and reduce costs for patients and payors. For example:

CVS Caremark uses industry expertise to negotiate discounts with manufacturers. These are passed on to plan sponsors and can be used to lower premiums or reduce cost-sharing for consumers.

We developed the capability for clients to apply negotiated discounts at the point-of-sale, to reduce a member's out-of-pocket cost for a prescription when they are at the pharmacy counter.

By encouraging the use of lower-cost, clinically equivalent medicines, such as generics and biosimilars, we can help patients achieve the same health outcomes at a more affordable cost.

We also lower costs through the Reduced RxTM program, which helps patients with high out-of-pocket costs afford their medications.

For more information on how CVS Health is working to ensure consumers have access to affordable medicines, visit our Rising Drug Prices information center. And to stay informed about the most talked-about topics in health care, register for content alerts and our bi-weekly health care newsletter.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
04/26CVS HEALTH : Teams Up with Job Corps to Enhance Workforce Development Opportunit..
AQ
04/26CVS HEALTH : Underscores Commitment to Safe Medication Disposal Ahead of Nationa..
PR
04/25CVS HEALTH : expands safe drug disposals in Ohio
AQ
04/25CVS HEALTH : Foundation Awards Grant to Leahy Clinic
AQ
04/25CVS HEALTH : Releases 11th Annual Corporate Social Responsibility Report
PR
04/24CVS HEALTH : MSDE DORS, CVS Health to Honor First Graduates of Retail Training P..
AQ
04/24CVS HEALTH : expands safe drug disposal at CVS Pharmacy locations in Ohio to hel..
AQ
04/24Glenview's Robbins says talk of Amazon's entering pharma is overblown
RE
04/23Humana, PE firms to buy hospice operator Curo Health for $1.4 billion
RE
04/20CVS HEALTH CORPORATION : To Hold First Quarter 2018 Conference Call
PR
More news
News from SeekingAlpha
04/26CVS HEALTH : A Store-Level Look At The Proposed Healthcare Giant 
04/23OAKMARK EQUITY AND INCOME FUND : Q1 2018 
04/21THE PASSIVE DGI CORE PORTFOLIO : Income, Safety, And Growth 
04/20Vilas Fund, LP Q1 '18 Letter To Partners - #28 Since Inception, Long Pharma 
04/1910 Dividend Growth Stocks For April 2018 
Financials ($)
Sales 2018 189 B
EBIT 2018 10 003 M
Net income 2018 5 761 M
Debt 2018 20 873 M
Yield 2018 3,18%
P/E ratio 2018 12,46
P/E ratio 2019 11,09
EV / Sales 2018 0,47x
EV / Sales 2019 0,44x
Capitalization 67 568 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 87,9 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-8.14%67 568
WALGREENS BOOTS ALLIANCE-10.49%64 458
EXPRESS SCRIPTS HOLDING CO2.52%42 390
MCKESSON CORPORATION-4.53%30 722
AMERISOURCEBERGEN-0.42%19 801
CARDINAL HEALTH1.78%19 625